The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib/II trial of durvalumab and chemoradiation (CRT) with carboplatin/paclitaxel for esophageal and gastroesophageal junction (GEJ) adenocarcinoma.
 
Megan Greally
No Relationships to Disclose
 
Daniela Molena
Honoraria - Novadaq Technologies
Travel, Accommodations, Expenses - Novadaq Technologies
 
Smita Sihag
No Relationships to Disclose
 
Abraham Jing-Ching Wu
Research Funding - CivaTech Oncology
 
Pari M. Shah
No Relationships to Disclose
 
Carly Fein
No Relationships to Disclose
 
Marinela Capanu
No Relationships to Disclose
 
David Paul Kelsen
No Relationships to Disclose
 
Yelena Yuriy Janjigian
Consulting or Advisory Role - Lilly; Pfizer
Research Funding - Amgen; Bayer; Boehringer Ingelheim; Genentech; Lilly; Roche
 
David H. Ilson
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly/ImClone; Merck; Pieris Pharmaceuticals; Roche/Genentech
 
Geoffrey Yuyat Ku
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Merck Sharp & Dohme
Research Funding - Aduro Biotech (Inst); Arog (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck (Inst); Pieris Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Aduro Biotech; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme